Nidia Carolina Moreno-Corona

Dr. Nidia Carolina Moreno-Corona

Imagine Institute for Genetic Diseases, Paris, Île-de-France, France
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2021 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
RTRomane Thouenon
Romane Thouenon
NMNidia Carolina Moreno-Corona
Nidia Carolina Moreno-Corona
LPLucie Poggi
Lucie Poggi
ADAnne Durandy
Anne Durandy
SKSven Kracker
Sven Kracker
Autosomal dominant gain-of-function mutations in the PIK3CD gene encoding the catalytic subunit p110δ of phosphoinositide 3-kinase-δ (PI3K-δ) or autosomal dominant loss-of-function mutations in the PIK3R1 gene encoding the p85α, p55α and p50α regulatory subunits cause Activated PI3-kinase-δ syndrome (APDS; referred as type 1 APDS and type 2 APDS, respectively). Consequences of these mutations are PI3K-δ hyperactivity. Clinical presentation described for both types of APDS patients is very variable, ranging from mild or asymptomatic features to profound combined immunodeficiency. Massive lymphoproliferation, bronchiectasis, increased susceptibility to bacterial and viral infections and, at a lesser extent, auto-immune manifestations and occurrence of cancer, especially B cell lymphoma, have been described for both types of APDS patients. Here, we review clinical presentation and treatment options as well as fundamental immunological and biological features associated to PI3K-δ increased signaling.

Verified
Journal Article
Open access
PDF file
OLOrestes López-Ortega
Orestes López-Ortega
NMNidia Carolina Moreno-Corona
Nidia Carolina Moreno-Corona
VCVictor Javier Cruz-Holguin
Victor Javier Cruz-Holguin
LGLuis Didier Gonzalez Garcia
Luis Didier Gonzalez Garcia
Addy Cecilia Helguera-RepettoAddy Cecilia Helguera-Repetto
Addy Cecilia Helguera-Repetto
Moisés León-JuárezMoisés León-Juárez
Moisés León-Juárez
The current obesity pandemic has been expanding in both developing and developed countries. This suggests that the factors contributing to this condition need to be reconsidered since some new factors are arising as etiological causes of this disease. Moreover, recent clinical and experimental findings have shown an association between the progress of obesity and some infections, and the functions of adipose tissues, which involve cell metabolism and adipokine release, among others. Furthermore, it has recently been reported that adipocytes could either be reservoirs for these pathogens or play an active role in this process. In addition, there is abundant evidence indicating that during obesity, the immune system is exacerbated, suggesting an increased susceptibility of the patient to the development of several forms of illness or death. Thus, there could be a relationship between infection as a trigger for an increase in adipose cells and the impact on the metabolism that contributes to the development of obesity. In this review, we describe the findings concerning the role of adipose tissue as a mediator in the immune response as well as the possible role of adipocytes as infection targets, with both roles constituting a possible cause of obesity.

Verified
Journal Article
Open access
PDF file
NMNidia Carolina Moreno-Corona
Nidia Carolina Moreno-Corona
OLOrestes López-Ortega
Orestes López-Ortega
CPCesar Augusto Perez-Martinez
Cesar Augusto Perez-Martinez
MMMacario Martínez-Castillo
Macario Martínez-Castillo
Luis Adrián De Jesús GonzálezLuis Adrián De Jesús González
Luis Adrián De Jesús González
Moisés León-JuárezMoisés León-Juárez
Moisés León-Juárez
Coronavirus disease (COVID-19) is an infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which can be asymptomatic or present with multiple organ dysfunction. Many infected individuals have chronic alterations associated with neuropsychiatric, endocrine, gastrointestinal, and musculoskeletal symptoms, even several months after disease onset, developing long-COVID or post-acute COVID-19 syndrome (PACS). Microbiota dysbiosis contributes to the onset and progression of many viral diseases, including COVID-19 and post-COVID-19 manifestations, which could serve as potential diagnostic and prognostic biomarkers. This review aimed to discuss the most recent findings on gut microbiota dysbiosis and its relationship with the sequelae of PACS. Elucidating these mechanisms could help develop personalized and non-invasive clinical strategies to identify individuals at a higher risk of experiencing severe disease progression or complications associated with PACS. Moreover, the review highlights the importance of targeting the gut microbiota composition to avoid dysbiosis and to develop possible prophylactic and therapeutic measures against COVID-19 and PACS in future studies.

14 March 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
RTRomane Thouenon
Romane Thouenon
LCLoïc Chentout
Loïc Chentout
NMNidia Carolina Moreno-Corona
Nidia Carolina Moreno-Corona
LPLucie Poggi
Lucie Poggi
ELEmilia Puig Lombardi
Emilia Puig Lombardi
SKSven Kracker
Sven Kracker
Here, we report on a heterozygous interferon regulatory factor 4 (IRF4) missense variant identified in three patients from a multigeneration family with hypogammaglobulinemia. Patients’ low blood plasmablast/plasma cell and naïve CD4 and CD8 T cell counts contrasted with high terminal effector CD4 and CD8 T cell counts. Expression of the mutant IRF4 protein in control lymphoblastoid B cell lines reduced the expression of BLIMP-1 and XBP1 (key transcription factors in plasma cell differentiation). In B cell lines, the mutant IRF4 protein as wildtype was found to bind to known IRF4 binding motifs. The mutant IRF4 failed to efficiently regulate the transcriptional activity of interferon-stimulated response elements (ISREs). Rapid immunoprecipitation mass spectrometry of endogenous proteins indicated that the mutant and wildtype IRF4 proteins differed with regard to their respective sets of binding partners. Our findings highlight a novel mechanism for autosomal-dominant primary immunodeficiency through altered protein binding by mutant IRF4 at ISRE, leading to defective plasma cell differentiation.

24 June 2021 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
NMNidia Carolina Moreno-Corona
Nidia Carolina Moreno-Corona
LCLoïc Chentout
Loïc Chentout
LPLucie Poggi
Lucie Poggi
RTRomane Thouenon
Romane Thouenon
CMCecile Masson
Cecile Masson
SKSven Kracker
Sven Kracker
Activated PI3-kinase-δ syndrome 2 (APDS2) is caused by autosomal dominant mutations in the PIK3R1 gene encoding the p85α, p55α, and p50α regulatory subunits. Most diagnosed APDS2 patients carry mutations affecting either the splice donor or splice acceptor sites of exon 11 of the PIK3R1 gene responsible for an alternative splice product and a shortened protein. The clinical presentation of APDS2 patients is highly variable, ranging from mild to profound combined immunodeficiency features as massive lymphoproliferation, increased susceptibility to bacterial and viral infections, bronchiectasis, autoimmune manifestations, and occurrence of cancer. Non-immunological features such as growth retardation and neurodevelopmental delay have been reported for APDS2 patients. Here, we describe a patient suffering from an APDS2 associated with a Smith–Magenis syndrome (SMS), a complex genetic disorder affecting, among others, neurological manifestations and review the literature describing neurodevelopmental impacts in APDS2 and other PIDs/monogenetic disorders associated with dysregulated PI3K signaling.

26 June 2020 in Scandinavian Journal of Immunology
Verified
Journal Article
Closed access
PDF file
NMNidia Carolina Moreno-Corona
Nidia Carolina Moreno-Corona
OLOrestes López-Ortega
Orestes López-Ortega
JHJose Mizael Flores Hermenegildo
Jose Mizael Flores Hermenegildo
LBLaura Berron‐Ruiz
Laura Berron‐Ruiz
JRJuan Carlos Rodríguez-Alba
Juan Carlos Rodríguez-Alba
GHGabriela Lopez Herrera
Gabriela Lopez Herrera